Li Y - Search Results

1

Synergistic association of FOXP3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer: A retrospective cohort study.

Zhao X, Li Y, Wang X, Wu J, Yuan Y, Lv S, Ren J. Zhao X, et al. Among authors: li y. Medicine (Baltimore). 2019 Dec;98(50):e18403. doi: 10.1097/MD.0000000000018403. Medicine (Baltimore). 2019. PMID: 31852159 Free PMC article.

2

Prognostic significance of Ubiquilin1 expression in invasive breast cancer.

Wang Y, Lu J, Zhao X, Feng Y, Lv S, Mu Y, Wang D, Fu H, Chen Y, Li Y. Wang Y, et al. Among authors: li y. Cancer Biomark. 2015;15(5):635-43. doi: 10.3233/CBM-150503. Cancer Biomark. 2015. PMID: 26406952

3

Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis.

Lv S, Wang Y, Sun T, Wan D, Sheng L, Li W, Zhu H, Li Y, Lu J. Lv S, et al. Among authors: li y, li w. Oncol Res Treat. 2018;41(7-8):450-455. doi: 10.1159/000488202. Epub 2018 Jun 15. Oncol Res Treat. 2018. PMID: 29902791

4

Functional CD3⁺CD8⁺PD1^- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.

Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan F, Li Y, Wang S, Morse MA, Hobeika A, Ren J, Lyerly HK. Lv S, et al. Among authors: li y. Clin Breast Cancer. 2019 Oct;19(5):e617-e623. doi: 10.1016/j.clbc.2019.04.001. Epub 2019 Apr 16. Clin Breast Cancer. 2019. PMID: 31101455

5

Long disease-free survival (48 months) in a breast cancer patient with ovarian and pelvic metastasis-a case report.

Feng Y, Zhao X, Lv S, Xiong B, Li Y, Zhang M. Feng Y, et al. Among authors: li y. Transl Cancer Res. 2020 Dec;9(12):7669-7675. doi: 10.21037/tcr-20-2031. Transl Cancer Res. 2020. PMID: 35117367 Free PMC article.

6

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test.

Yuan K, Wu J, Zhao Y, Lyu S, Zhou Q, Shi F, Li Y, Song Q. Yuan K, et al. Among authors: li y. Diagn Pathol. 2022 Sep 10;17(1):68. doi: 10.1186/s13000-022-01249-w. Diagn Pathol. 2022. PMID: 36088412 Free PMC article.

7

Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study.

Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y, Liu C, Li P, Xiong B, Guo Y, Lv D, Liu Y, Mao T, Yuan K, Cheng X, Li Y, Wang X. Li Y, et al. Among authors: li p. Anticancer Drugs. 2023 Jul 1;34(6):763-774. doi: 10.1097/CAD.0000000000001456. Epub 2022 Nov 19. Anticancer Drugs. 2023. PMID: 36730296 Clinical Trial.

8

Expression and function of cytokine interleukin-22 gene in the tumor microenvironment of triple negative breast cancer.

Xiao Y, Zhao X, Guo Y, Li Y. Xiao Y, et al. Among authors: li y. Cytokine. 2024 Jul;179:156590. doi: 10.1016/j.cyto.2024.156590. Epub 2024 Apr 5. Cytokine. 2024. PMID: 38581864

9

Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study.

Wang Y, Sun T, Wan D, Sheng L, Li W, Zhu H, Li Y, Lu J. Wang Y, et al. Among authors: li y, li w. Onco Targets Ther. 2015 Nov 11;8:3337-48. doi: 10.2147/OTT.S91166. eCollection 2015. Onco Targets Ther. 2015. PMID: 26648738 Free PMC article.

10

Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer.

Wu M, Yuan K, Lyu S, Li Y. Wu M, et al. Among authors: li y. World J Surg Oncol. 2022 Jun 24;20(1):214. doi: 10.1186/s12957-022-02683-2. World J Surg Oncol. 2022. PMID: 35751103 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240,776 results

Search Page

Filters